Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

Which of the statements about the American College of Rheumatology guidance statement for diagnosing and managing VEXAS are correct?

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 ...

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and ...

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, ...

In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare penny stocks to buy now. On September 8, 2025, ImmunityBio Inc. unveiled promising Phase 2 QUILT-3.055 trial results at the IASLC World ...

Objective To elucidate the impact of lymphopenia on critical COVID-19 patient outcomes. Methods We conducted a multicenter prospective cohort study across five hospitals in Portugal and Brazil from ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News GroupNews Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] ...